A collection of insights detailing the top opportunities in Indian consumer discretionary
Read More
A collection of insights on achieving balance between innovation and regulation in FinTech
A collection detailing the developments in performance and regulation of banks in APAC.
A collection of insights detailing the Fintech landscape in APAC and what to look out for
A collection of insights detailing global liquidity patterns and its developments
Entity | Insights | Analytics | News | Discussion | Filings | Reports |
Raffles Medical Group (RFMD SP, BSL.SI) is a healthcare company listed on the Singapore Exchange (SGX). The company provides a range of healthcare services, including primary care, specialist medical services, and hospital services. In this article, we will focus on Raffles Medical Share Price and provide an overview of the company’s financial performance, factors that affect its share price, its ownership structure, and its investment prospects. We will also highlight the independent research available on Smartkarma, a leading investment research platform where top independent analysts publish their research on companies such as Raffles Medical.
Raffles Medical Group’s Financial Performance
Raffles Medical Group’s financial performance has been relatively stable in recent years. In 2021, the company reported a revenue of SGD 546.9 million, up 1.2% from the previous year. However, the company’s net profit after tax decreased by 35.4% to SGD 41.9 million due to the impact of the COVID-19 pandemic. Raffles Medical’s earnings per share also decreased by 37.4% from SGD 4.02 in 2020 to SGD 2.52 in 2021.
Despite the challenging environment, Raffles Medical has continued to expand its services and facilities. The company opened a new medical centre in Raffles Place, Singapore, in 2021, which provides specialist medical services, general practice, and diagnostic imaging services. Raffles Medical has also announced plans to build a new hospital in Shanghai, China, which is expected to open in 2025.
Factors Affecting Raffles Medical Share Price
Raffles Medical’s share price is influenced by various factors, including the company’s financial performance, industry developments, and market trends. For example, Raffles Medical’s share price may increase if the company reports better-than-expected financial results or if there is positive news in the healthcare industry. Conversely, the company’s share price may decrease if it reports weak financial results or if there is negative news in the healthcare industry.
Over the past five years, Raffles Medical’s share price has fluctuated between SGD 0.92 and SGD 1.62. The share price has been relatively stable in recent months, with the stock trading at around SGD 1.00 to SGD 1.10.
Is Raffles Medical a Good Stock?
Raffles Medical has been a consistent performer in the healthcare industry in Singapore. The company’s strong brand recognition, diversified business lines, and strategic expansion plans are some of its strengths. However, Raffles Medical also faces competition from other healthcare companies, as well as regulatory risks and operational challenges.
Investors interested in Raffles Medical can benefit from the independent research available on Smartkarma. Top independent analysts, such as Geoff Howie, Jason Yap, CFA, Kemp Dolliver, CFA, Maybank Research, Shifara Samsudeen, ACMA, CGMA, Tina Banerjee, and Xinyao (Criss) Wang, have written great research on Raffles Medical on Smartkarma, providing valuable insights into the company’s financial performance, competitive landscape, and investment prospects.
Ownership of Raffles Medical Group
Raffles Medical is a private healthcare company, with no government ownership. The company’s major shareholders are the founders of Raffles Medical, Dr. Loo Choon Yong and Dr. Alfred Loh. As of 31 December 2021, Dr. Loo and Dr. Loh owned 29.82% and 29.49% of Raffles Medical’s shares, respectively.
Healthcare Stocks to Buy in Singapore
Raffles Medical is one of the top healthcare stocks to consider investing in, along with other prominent healthcare companies such as Singapore Medical Group, IHH Healthcare, and Q&M Dental Group. These companies operate in different segments of the healthcare industry, providing a range of services to customers in Singapore and other parts of the world. Investors interested in the healthcare sector can benefit from the growth potential of these companies, as demand for healthcare services is expected to continue to rise in Singapore and other countries.
Conclusion
Raffles Medical Group is a leading healthcare company in Singapore, providing a range of services to customers across the country. The company’s financial performance has been relatively stable, despite the challenges posed by the COVID-19 pandemic. Raffles Medical’s share price is influenced by various factors, including the company’s financial performance, industry developments, and market trends.
Investors interested in Raffles Medical can benefit from the independent research available on Smartkarma, where top independent analysts provide valuable insights into the company’s financial performance, competitive landscape, and investment prospects. Raffles Medical is one of the top healthcare stocks to consider investing in, along with other prominent healthcare companies such as Singapore Medical Group, IHH Healthcare, and Q&M Dental Group.
Overall, Raffles Medical Group’s strong brand recognition, diversified business lines, and strategic expansion plans make it a good stock to consider investing in for investors looking to gain exposure to the healthcare sector in Singapore.
A collection of insights detailing the top trade ideas in China from our network
Smartkarma adds new Insight Providers to its roster, expanding the depth and breadth of its coverage
SINGAPORE, 22 Feb 2023: Smartkarma, the independent investment research network, has announced new additions to its growing base of Insight Providers.
The following additions to Smartkarma’s pool of Insight Providers will further elevate the breadth and depth of global coverage available on the platform. Subscribers will benefit from the actionable and data-backed insights produced on the platform, and receive a more holistic view of the global economy.
- Andreas Steno, Steno Research
Andreas is the founder and Head of Research of the European Power Research house “Steno Research.” Steno Research is a new macro and geopolitical research house. Andreas’ expertise lies in the macro strategy, energy, real estate and equity spaces. - Mikkel Rosenvold, Steno Research
Mikkel is a geopolitical Analyst based out of Copenhagen, Denmark. His fields of expertise span European Politics, Global Conflicts, Geopolitical Strategy and Political Economy. Steno Research has an international team and a strong network of sources and partners around the world. - Alexis Dwek, Starling Advisors
Alexis has a strictly pan-European focus, and is here to build that niche on Smartkarma. With a high calibre buyside background and a strong entrepreneurial spirit, he recently started his independent research business, Starling Advisors. - Shawn Yang, Blue Lotus Research Institute
Shawn has extensive experience in the internet industry and investment banking. His main focus is China’s internet sector. Blue Lotus Research Institute regularly covers about 60 high tech companies in Hong Kong, US ADR and Chinese domestic bourses. They have solid on the ground experience with the goal to expand their coverage to all Asian internet names.
Stay in the loop and check out their insights on Smartkarma.
About Smartkarma
Smartkarma is the independent investment research network that provides differentiated, independent analysis on companies, markets, and industries across the world. Smartkarma’s online platform empowers asset managers and private accredited investors who want to access market-moving, differentiated intelligence; corporates who need to maximise their outreach; and analysts who wish to reach global investors with their written reports and bespoke services. In 2021, Smartkarma received the Knowledge Enterprise Award at the Singapore FinTech Festival Global FinTech Awards. Smartkarma is backed by notable investors such as Sequoia Capital, SGX, Wavemaker Partners, Jungle Ventures, and Enterprise Singapore. Learn more at smartkarma.com
A collection of insights detailing the digital movement in China’s internet space